Engitix Therapeutics
Athiva Shanker joined Engitix in 2020.
As Associate Director, Biospecimens and tissue-based assay, Athiva leads on validating disease targets for novel therapies in fibrosis and cancer, clinical biospecimen acquisition, and liaising with KOL’s.
Athiva brings rich and varied experiences to her role at Engitix gained from working and interacting with a diverse range of stakeholders across the healthcare sector.
Previously she worked as a Target Validation Scientist at Immunocore, a Clinical Trials Monitor, covering a range of different therapeutic indications, at IQVIA (formerly Quintiles), and as a General Dental Practitioner in India.
Athiva leads the biospecimen acquisition and tissue-based assay development efforts at Engitix.
Athiva received a PhD in Cancer Biology from the University of Dundee, Scotland.
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.